Physician profile
Grant E Lee
NPI 1700109501
$7,598.46
in general payments reported to CMS, 2019-2025
27 companies · $1,947 in 2025
The $1,947 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $918 · 2021: $771 · 2022: $913 · 2023: $852 · 2024: $1,326 · 2025: $1,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,107 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,106.80 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,434.26 | 2019-2025 | Rocklatan, Tryptyr, Clareon |
| Abbvie INC. | $1,278.76 | 2022-2025 | |
| Allergan, INC. | $1,074.28 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $705.21 | 2022-2025 | Miebo, Vyzulta, Envista Mx60 Iol |
| Novartis Pharmaceuticals Corporation | $474.59 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $329.74 | 2019-2021 | |
| Amgen INC. | $319.11 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $259.74 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $224.02 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $211.50 | 2019-2022 | |
| Thea Pharma INC. | $207.26 | 2023-2025 | Iyuzeh |
| Harrow Eye, LLC | $188.34 | 2024-2025 | Vevye, Tobradex St |
| Horizon Therapeutics Plc | $176.66 | 2022-2023 | Tepezza |
| Oyster Point Pharma, INC. | $157.88 | 2022-2024 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $114.48 | 2019-2023 | Flarex |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $94.57 | 2019-2022 | |
| Rxsight INC | $77.07 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Astellas Pharma US INC | $48.65 | 2025 | Izervay |
| Shire North American Group INC | $42.03 | 2019 | |
| Glaukos Corporation | $32.12 | 2021-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $28.11 | 2025 | Xdemvy |
| Akorn Operating Company LLC | $22.46 | 2021 | |
| Mallinckrodt Hospital Products INC. | $20.83 | 2022 | |
| Dompe US, INC. | $20.71 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ani Pharmaceuticals, INC. | $18.90 | 2025 | Purified Cortrophin Gel |
| Optos, INC. | $17.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.